American Society of Hirudotherapy

Leech Granulin-A

Granulin-family peptide identified in Hirudo medicinalis — putative growth-factor / wound-healing analog (mechanistic only).

Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Leech Granulin-A compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaLeech Granulin-A6 kDa
Molecular weight (kilodaltons) of Leech Granulin-A (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Granulin-family peptide identified in Hirudo medicinalis — putative growth-factor / wound-healing analog (mechanistic only).
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound

Clinical translation limit

Leech granulin-A is documented at the sequence level only. Hypothesized growth-factor analog activity does NOT establish clinical wound-healing efficacy. No FDA-approved derivative exists.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Molecular weight
6,000 Da
Source species
Hirudo medicinalis
Discovered
2018
Leech Granulin-A molecular structure

Biological Targets

  • growth-factor signaling (mechanism under characterization)

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.